ETUPTAMIG
UNII J4G6KKD4QK
Substance Identification & Data
This profile provides standardized clinical and technical data for Etuptamig, uniquely identified by the FDA Unique Ingredient Identifier (UNII) J4G6KKD4QK.
Technical mappings include the Chemical Abstracts Service (CAS) Registry Number 3009874-10-3 and the RxNorm Concept ID (RxCUI) N/A. Explore the sections below for detailed nomenclature and a complete directory of NDC-listed products containing this ingredient.
J4G6KKD4QK
3009874-10-3
N/A
Detailed Substance Profile
Preferred Name
ETUPTAMIG
Official standardized name for this substance within the FDA UNII nomenclature system.
NCI Thesaurus
National Cancer Institute reference terminology for clinical and research data.
INN ID
13402
Sequential identifier assigned via the WHO International Nonproprietary Name program.
Substance Type
Etuptamig
ISO 11238 classification category (e.g., Chemical, Polymer, Protein).
Synonyms and Nomenclature
This section provides a complete list of nomenclature and identifier mappings for Etuptamig. Identifiers are organized into official regulatory terms, commercial trade names, and technical systematic synonyms used to ensure accurate identification across clinical pharmaceutical databases, regulatory filings, and electronic health records.
Common Names & Synonyms
Etuptamig
Immunoglobulin [495-alanine,496-alanine,627-serine,629-alanine,668-valine,696-arginine,697-phenylanalnine,de-C-terminal lysine], bispecific, anti-(human CD3 antigen ε-chain) (human-Mus musculus monoclonal TPP 13461 λ-chain) fusion protein with peptide linker (synthetic 18-amino acid) fusion protein with human-Mus musculus monoclonal TPP 13461 γ1-chain, disulfide with immunoglobulin [486-alanine,487-alanine,618-tryptophan,de-C-terminal lysine] anti-(human B7 homolog protein B7H6) (human-Mus musculus monoclonal TPP 13461 κ-chain) fusion protein with peptide linker (synthetic 18-amino acid) fusion protein with human-Mus musculus monoclonal TPP 13461 γ1-chain
etuptamig [INN]
fused chain L-kappa-H-gamma1 anti-NCR3LG1 (1-698) (knob) [L-kappa anti-NCR3LG1 (1-214) [V-KAPPA (Homo sapiens IGKV1-16*01 (85.3%) -IGKJ2*01 (90.9%) Q120>A (100), CDR-IMGT [6.3.9] (27-32.50-52.89-97)) (1-107)-Homo sapiens IGKC*01 (100%) Km3 A45.1, V101 (CKAPPA A45.1 (153'), V101 (191')) (108'-214')] -38-mer(tetraglycylserylbis( EGKSSGSGSESKST)-tetraglycylseryl) linker (215-252) -[H-gamma-1 heavy chain anti-NCR3LG1 (253-698) [VH (Homo sapiens IGHV1-46*01 (81.6%) -(IGHD) -IGHJ5*01 (92.3%), CDR-IMGT [8.8.10] (278-285.303-310.349-358)) (253-369)-Homo sapiens IGHG1*03, G1m3, nG1m1, CH1 R120, CH3 E12, M14,6-G1v14 CH2 A1.3, A1.2, 14-G1v32 CH3 W22 (knob) (CH1 R120 (466) (370-467), hinge 1-15 (468-482), CH2 L1.3>A (486), L1.2>A (487) (483-592), CH3 E12 (608), M14 (610), T22>W (618) (593-697), CHS K2>del (698)) (370-698)]]; fused chain L-lambda6-H-gamma1 anti-CD3E (1-707) (hole) [L-lambda6 anti-CD3E (1'-215') [V-LAMBDA Musmus/Homsap (Mus musculus IGLV1*01 (82.3%) -IGLJ1*01 (100%)/Homo sapiens IGLV7-46*01 (76.8%) -IGLJ3*02 (100%), CDR-IMGT [9.3.9] (26'-34'.52'-54'.91'-99')) (1'-109') -Homo sapiens IGLC6*01 (100%) (C-LAMBDA6) (110'-215')] -38-mer (tetraglycylseryl-bis(EGKSSGSGSESKST)-tetraglycylseryl) linker (216'-253') -[H-gamma-1 anti-CD3E (254'-707') [VH Musmus/Homsap (Mus musculus IGHV10-1*04 (93.0%) -(IGHD) -IGHJ3*01 (100%)/Homo sapiens IGHV3-73*01 (87.0%) -(IGHD) -IGHJ6*01 (81.8%) T123>L (373'), S128>A (378'), CDR-IMGT [8.10.16] (279'-286'.304'-313'.352'-367')) (254'-378')-Homo sapiens IGHG1*03, G1m3, nG1m1, CH1 R120, CH3 E12, M14, 6-G1v14 CH2 A1.3, A1.2,14-G1v33 CH3 S22, A24, V86 (hole), 10-G1v83 CH3 R115, F116 (CH1 R120 (475') (379'-476'), hinge 1-15 (477'-491'), CH2 L1.3>A (495'), L1.2>A (496') (492'-601'), CH3 E12 (617'), M14 (619'), T22>S (627'), L24>A (629'), Y86>V (668'), H115>R (696'), Y116>F (697') (602'-706'), CHS K2>del (707')) (379'-707')]]; dimer (478-487':481-490')-bisdisulfide, produced in Chinese hamster ovary (CHO) cells, cell line CHO-K1
immunoglobulin L-kappa-H-gamma1_L-lambda-H-gamma1, anti-[Homo sapiens NCR3LG1 (natural killer cell cytotoxicity receptor 3 ligand 1, B7 homolog 6, B7-H6)] and anti-[Homo sapiens CD3E (CD3 epsilon, Leu-4)], monoclonal antibody, bispecific
